Lista de obras - Min H Kang - Dominio Público Uruguay

A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma

artículo científico publicado en 2016

A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar).

artículo científico publicado en 2001

A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.

artículo científico publicado en 2002

Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression

artículo científico publicado en 2015

Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo.

artículo científico publicado en 2007

Bcl-2 family of proteins as therapeutic targets in genitourinary neoplasms.

artículo científico

Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy

artículo científico publicado en 2009

Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models

artículo científico publicado en 2018

C22:0- and C24:0-dihydroceramides confer mixed cytotoxicity in T-cell acute lymphoblastic leukemia cell lines.

artículo científico publicado en 2013

Caspase-dependent Mcl-1 cleavage and effect of Mcl-1 phosphorylation in ABT-737-induced apoptosis in human acute lymphoblastic leukemia cell lines.

artículo científico publicado en 2014

Ceramide synthase-6 confers resistance to chemotherapy by binding to CD95/Fas in T-cell acute lymphoblastic leukemia

artículo científico publicado en 2018

Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives.

artículo científico publicado en 2017

Cytotoxic activity of difluoromethylornithine compared with fenretinide in neuroblastoma cell lines

artículo científico publicado en 2018

Cytotoxicity and molecular activity of fenretinide and metabolites in T-cell lymphoid malignancy, neuroblastoma, and ovarian cancer cell lines in physiological hypoxia

artículo científico publicado en 2019

DNA-PK as an Emerging Therapeutic Target in Cancer

scientific article published on 17 July 2019

Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer.

artículo científico publicado en 2011

Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis

artículo científico publicado en 2016

Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma.

artículo científico publicado en 2012

Evaluation of cytarabine against Ewing sarcoma xenografts by the pediatric preclinical testing program ⬇️

artículo científico publicado el 1 de diciembre de 2010

Fenretinide cytotoxicity is independent of both constitutive and pharmacologically modulated glutathione levels in pediatric acute lymphoblastic leukemia cells cultured at hypoxia.

artículo científico publicado en 2012

Fenretinide metabolism in humans and mice: utilizing pharmacological modulation of its metabolic pathway to increase systemic exposure

artículo científico publicado en 2011

Fenretinide via NOXA Induction, Enhanced Activity of the BCL-2 Inhibitor Venetoclax in High BCL-2-Expressing Neuroblastoma Preclinical Models

scientific article published on 04 September 2019

Hydrophilic interaction liquid chromatography-tandem mass spectrometric approach for simultaneous determination of safingol and D-erythro-sphinganine in human plasma

artículo científico publicado en 2019

Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor

artículo científico publicado en 2016

Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program.

artículo científico publicado en 2016

Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program

artículo científico publicado en 2015

Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program

artículo científico publicado en 2014

Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program.

artículo científico publicado en 2011

Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program

artículo científico publicado en 2013

Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling

artículo científico publicado en 2011

Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program.

artículo científico publicado en 2010

Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program

artículo científico publicado en 2014

Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program

artículo científico publicado en 2011

Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program.

artículo científico publicado en 2017

Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program.

artículo científico publicado en 2011

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program

artículo científico publicado en 2013

Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program

artículo científico publicado en 2013

Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program

scientific article published on February 2010

Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program

artículo científico publicado en 2013

Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program.

artículo científico publicado en 2010

Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.

artículo científico publicado en 2010

Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.

artículo científico publicado en 2014

Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.

artículo científico publicado en 2013

Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program.

artículo científico publicado en 2015

Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program.

artículo científico publicado en 2016

Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.

artículo científico publicado en 2012

Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program

artículo científico publicado en 2013

Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program

artículo científico publicado en 2014

Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program

artículo científico publicado en 2011

Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program

artículo científico publicado en 2010

Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program

artículo científico publicado en 2014

Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.

artículo científico publicado en 2012

Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program.

artículo científico publicado en 2011

Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program.

artículo científico publicado en 2013

Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program.

artículo científico publicado en 2011

Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program.

artículo científico publicado en 2016

Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program.

artículo científico publicado en 2010

Initial testing of aplidin by the pediatric pre-clinical testing program.

artículo científico publicado en 2009

Initial testing of lenalidomide by the pediatric preclinical testing program

artículo científico publicado en 2011

Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program

artículo científico publicado en 2011

Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program

artículo científico publicado en 2012

Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).

artículo científico publicado en 2010

Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program.

artículo científico publicado en 2010

Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.

scientific article published on 19 October 2011

Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program

artículo científico publicado en 2010

Initial testing of topotecan by the pediatric preclinical testing program.

artículo científico publicado en 2010

MYC transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastoma

artículo científico publicado en 2020

Metabolic characteristics of 13-cis-retinoic acid (isotretinoin) and anti-tumour activity of the 13-cis-retinoic acid metabolite 4-oxo-13-cis-retinoic acid in neuroblastoma

artículo científico publicado en 2014

Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235

artículo científico publicado en 2015

National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing

artículo científico publicado en 2010

P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models.

artículo científico publicado en 2017

Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program.

artículo científico publicado en 2015

Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts.

artículo científico publicado en 2012

Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial

artículo científico publicado en 2017

Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial

artículo científico publicado en 2018

Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium.

artículo científico publicado en 2013

Phase I trial of fenretinide lym-x-sorb oral powder in adults with solid tumors and lymphomas

artículo científico publicado en 2011

Preservation of high glycolytic phenotype by establishing new acute lymphoblastic leukemia cell lines at physiologic oxygen concentration

artículo científico publicado en 2015

Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study.

artículo científico publicado en 2014

Reactive Oxygen Species-Mediated Synergism of Fenretinide and Romidepsin in Preclinical Models of T-cell Lymphoid Malignancies.

artículo científico publicado en 2017

Reversal of multidrug resistance: lessons from clinical oncology.

artículo científico publicado en 2002

Role of OCT4 in cancer stem-like cells and chemotherapy resistance

artículo científico publicado en 2019

Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program

artículo científico publicado en 2010

Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.

artículo científico publicado en 2014

Synergistic activity of rapamycin and dexamethasone in vitro and in vivo in acute lymphoblastic leukemia via cell-cycle arrest and apoptosis.

artículo científico publicado en 2011

Taxanes in hormone-refractory prostate cancer.

artículo científico publicado en 1999

Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program.

artículo científico publicado en 2011

Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program.

artículo científico publicado en 2011

The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel.

artículo científico publicado en 2001

The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma

artículo científico publicado en 2014

pH gradient-liquid chromatography tandem mass spectrometric assay for determination of underivatized polyamines in cancer cells.

artículo científico publicado en 2018

Lista de obras de Min H Kang

A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma

A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar).

A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.

Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression

Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo.

Bcl-2 family of proteins as therapeutic targets in genitourinary neoplasms.

Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy

Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models

C22:0- and C24:0-dihydroceramides confer mixed cytotoxicity in T-cell acute lymphoblastic leukemia cell lines.

Caspase-dependent Mcl-1 cleavage and effect of Mcl-1 phosphorylation in ABT-737-induced apoptosis in human acute lymphoblastic leukemia cell lines.

Ceramide synthase-6 confers resistance to chemotherapy by binding to CD95/Fas in T-cell acute lymphoblastic leukemia

Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives.

Cytotoxic activity of difluoromethylornithine compared with fenretinide in neuroblastoma cell lines

Cytotoxicity and molecular activity of fenretinide and metabolites in T-cell lymphoid malignancy, neuroblastoma, and ovarian cancer cell lines in physiological hypoxia

DNA-PK as an Emerging Therapeutic Target in Cancer

Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer.

Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis

Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma.

Evaluation of cytarabine against Ewing sarcoma xenografts by the pediatric preclinical testing program ⬇️

Fenretinide cytotoxicity is independent of both constitutive and pharmacologically modulated glutathione levels in pediatric acute lymphoblastic leukemia cells cultured at hypoxia.

Fenretinide metabolism in humans and mice: utilizing pharmacological modulation of its metabolic pathway to increase systemic exposure

Fenretinide via NOXA Induction, Enhanced Activity of the BCL-2 Inhibitor Venetoclax in High BCL-2-Expressing Neuroblastoma Preclinical Models

Hydrophilic interaction liquid chromatography-tandem mass spectrometric approach for simultaneous determination of safingol and D-erythro-sphinganine in human plasma

Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor

Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program.

Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program

Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program

Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program.

Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program

Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling

Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program.

Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program

Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program

Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program.

Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program.

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program

Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program

Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program

Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program

Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program.

Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.

Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.

Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.

Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program.

Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program.

Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.

Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program

Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program

Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program

Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program

Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program

Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.

Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program.

Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program.

Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program.

Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program.

Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program.

Initial testing of aplidin by the pediatric pre-clinical testing program.

Initial testing of lenalidomide by the pediatric preclinical testing program

Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program

Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program

Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).

Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program.

Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.

Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program

Initial testing of topotecan by the pediatric preclinical testing program.

MYC transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastoma

Metabolic characteristics of 13-cis-retinoic acid (isotretinoin) and anti-tumour activity of the 13-cis-retinoic acid metabolite 4-oxo-13-cis-retinoic acid in neuroblastoma

Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235

National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing

P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models.

Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program.

Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts.

Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial

Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial

Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium.

Phase I trial of fenretinide lym-x-sorb oral powder in adults with solid tumors and lymphomas

Preservation of high glycolytic phenotype by establishing new acute lymphoblastic leukemia cell lines at physiologic oxygen concentration

Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study.